Soligenix is a late-stage biopharmaceutical company that researches and develops novel vaccines for the treatment of cancer and infectious diseases.Read more
$ < 1M
Soligenix's revenue is the ranked 28th among it's top 10 competitors. The top 10 competitors average 4.3B. Over the last three quarters, Soligenix's revenue has decreased by 65.1%. Specifically, in Q3 2021's revenue was $ < 1M; in Q1 2021, it was $ < 1M; in Q4 2020, it was $ < 1M.